Utah Medical Products

Utah Medical Products

Utah Medical Products was founded in 1978 by Kevin Cornwell, who continues to serve as Chairman and CEO. The company designs, manufactures, and distributes disposable medical devices for neonatal, obstetrics, gynecology, and critical care. Most competitors in the medical device space outsource at least some production; Utah Medical owns its manufacturing facilities, which gives it unusual control over margins and quality in a cost-sensitive corner of healthcare. The product portfolio spans neonatal intensive care catheters, fetal monitoring sensors, and labor and delivery disposables, alongside blood pressure monitoring components and gynecologic surgical devices. The company sells directly to hospitals and through distributors in the United States and the United Kingdom, with additional sales into select European markets. A key manufacturing subsidiary, Utah Medical Products Limited, operates from Athlone, Ireland — a geographic setup that places production inside the EU regulatory zone while the parent stays anchored in the US Mountain West. The firm reported revenues of roughly $50 million in recent fiscal years (public record) — a small cap that survives next to the Johnson & Johnsons and Medtronics of the world by staying narrow and self-contained. In September 2024 Utah Medical Products disclosed the retirement of CFO Brian Koopman, ending a multi-decade tenure for one of the longest-serving financial officers in the micro-cap medical device segment (per public filings, 2024). The company remains listed on NASDAQ under the ticker UTMD and has historically returned capital to shareholders through regular dividends rather than acquisition-driven growth. The structural differentiator is vertical integration at a scale where it shouldn't work. Most small-cap device makers are fabless; Utah Medical runs its own injection molding, extrusion, and assembly operations. That architecture gives it the cost profile of a larger manufacturer without the complexity of a multi-division conglomerate — and it is one of the few publicly listed medical device firms where the founding CEO still controls the company's strategic direction after more than four decades.